ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in functional status
Timeframe: baseline and 1 year after pediatric intensive care unit discharge
Change in health-related quality of life
Timeframe: baseline and 1 year after pediatric intensive care unit discharge
The proportion of children with a new morbidity
Timeframe: baseline and 1 year after pediatric intensive care unit discharge
All-cause mortality at hospital discharge or 90-days
Timeframe: 90 days after the day of illness on which patients from the two cohorts are matched
Comparative change in one-year functional status
Timeframe: baseline and 1 year after pediatric intensive care unit discharge
Comparative change in one-year health-related quality of life
Timeframe: baseline and 1 year after pediatric intensive care unit discharge